AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06491238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light Intensity Exercise
Description: 12 weeks light intensity strength and endurance NeuroWell exercise program, specifically developed for individuals with neurological disorders or injuries. Participants have the intensity goals descripted in the experimental arm.
Study NCT06491238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Exercise
Description: 12 weeks moderate intensity strength and endurance NeuroWell exercise program, specifically developed for individuals with neurological disorders or injuries. Participants have the intensity goals descripted in the experimental arm.
Study NCT05807958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin Prick Automated Test
Description: A skin prick automated test will be performed in each participant.
Study NCT06709391 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fusion surgery
Description: After anaesthesia, the surgical area is identified through intraoperative fluoroscopy. After sterile draping, incision is made through skin and subcutaneous fat. Dissection is performed bilaterally down to the facet joints and transverse processes. Intraoperative fluoroscopy or computed tomography is performed to verify the surgical level. When the dissection is complete, randomization takes place.~Randomization to fusion (active treatment):~Pedicle screws are placed. Interbody cages may be used. Fluoroscopy or intraoperative computed tomography with or without intraoperative navigation is performed for correct implant positioning. Decortication is performed in the surgical area, and the cartilage in the facet joints is partially removed to allow fusion. Local bone graft is used and placed in the surgical area. Rods are placed in the screws and the fixation system is locked. Local anaesthesia is given in the surgical area. Fascia, subcutaneous tissue, and skin is sutured.
Study NCT06709391 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Non-fusion surgery
Description: After anaesthesia, the surgical area is identified through intraoperative fluoroscopy. After sterile draping, incision is made through skin and subcutaneous fat. Dissection is performed bilaterally down to the facet joints and transverse processes. Intraoperative fluoroscopy or computed tomography is performed to verify the surgical level. When the dissection is complete, randomization takes place.~Randomization to non-fusion surgery (control):~No implants are placed. No decortication is performed. The facet joints are left intact. Local anaesthesia is given in the surgical area. Fascia, subcutaneous tissue and skin is sutured.
Study NCT06716606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab will be administered.
Study NCT06742268 — intervention group
Intervention type: OTHER
Intervention: Single vision spectacles
Description: Other interventions for myopia treatment, except for glasses, will not be provided.
Study NCT06749613 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: digestive enzymes
Description: A jar or single-dose sachets containing the digestive enzymes in the form of powder will be provided to each patient at the study entry. Patients will be instructed to use the powder formulation according to manufacturer instructions and according to the meals that they consume per day, for 1 month. Participants will be asked to return the jar or the single dose sachets with the remaining product to assess compliance either by weighting the jar or by counting the number of single-dose sachets returned. To reduce the placebo effect, patients will be misinformed that half will take a placebo formulation, randomly. Participants will be asked to return the jar or the single-dose sachets with the remaining product to assess compliance either by weighting the jar or by counting the number of single-dose sachets returned.
Study NCT06749951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for insomnia (CBT-I)
Description: Five 60-90 minutes weekly sessions delivered by an appropriately trained cardiac nurse at a cardiology department. The CBT-I intervention will follow a manualized treatment protocol developed by Espie and colleagues (Espie et al. 2001, 2007, 2008) and evaluated in a number of published RCTs using CBT-I. The key components of this intervention include sleep hygiene advice, stimulus control, sleep restriction, relaxation training, and cognitive restructuring.
Study NCT06749951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene Advice
Description: Sleep well is a 16-page written brochure developed by the Directorate of Health in Norway for dissemination to patients with sleep problems including insomnia. It covers general sleep hygiene advice (setting a regular bed-time, avoiding stimulants, alcohol and exercise in the evening, sleeping in a quiet bedroom, advice of practicing relaxation technique and postpone worries).
Study NCT06761417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone liposome
Description: Mitoxantrone liposome: 16 mg/m\^2, d1; Each 21-day cycle was used for a total of 4-6 cycles.
Study NCT06761417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m\^2, d1-14, bid; Each 21-day cycle was used for a total of 4-6 cycles.
Study NCT06761417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib: according to patient weight: 8mg/ day in patients \<35kg; 10mg/ day for patients with 35kg≤ patient weight ≤50kg; 12mg/ day for patients > 50kg; d1-14; Each 21-day cycle was used for a total of 4-6 cycles.
Study NCT06766513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actimetry
Description: actimetry will be performed continuously during these 104 hours.
Study NCT06766513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subjective assessments
Description: The subjective assessments of the patient's awake/sleep state will be collected every 2 hours during the night and at least 3 times during the day, for a total of at least 8 assessments per 24-hour period, over a duration of 104 consecutive hours (slightly more than 4 days, starting at midnight and ending at 8 :00 AM, to cover 4 full days and 4 full nights).
Study NCT06766513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: MOCA : Montreal Cognitive Assessment
Study NCT06766513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: SF-36 The Short Form (36)
Study NCT06766513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: CRS-R (Coma Recovery Scale-Revised)
Study NCT06766513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: GOSE (Glasgow Outcome Scale-Extended)
Study NCT06766513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: GCS (Glasgow Coma Scale)
Study NCT06766461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double dosing of beta-lactam antibiotic
Description: This arm will receive double dosing of beta-lactam antibiotics for the first 48 hours after inclusion.
Study NCT06764927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cryoprecipitate Intercept Fibrinogen Complex (IFC)
Description: INTERCEPT Fibrinogen Complex is a pathogen-reduced cryoprecipitated fibrinogen complex derived from human plasma. It contains fibrinogen, Factor XIII, and von Willebrand factor to achieve stable clot formation and restore hemostasis1. Recently approved by the US Food and Drug Administration, it is used for the treatment of bleeding associated with fibrinogen deficiency.
Study NCT06764927 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cryoprecipitate Antihemophilic Factor (AHF)
Description: Cryoprecipitate Antihemophilic Factor (AHF), also known as cryo, is a frozen blood product prepared from blood plasma. It is used for fibrinogen supplementation, particularly for hypofibrinogenemia fibrinogen, anemia associated with bleeding or congenital deficiency.
Study NCT06769074 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: PRP injection into the midurethra and its instillation into urinary bladder
Study NCT06765083 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: POCUS of the hip
Description: POCUS of the hip (proximal femur) by the (resident) emergency physician, prior to radiograph imaging.
Study NCT06766045 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Ultrasound
Description: Diaphragmatic ultrasound was performed bedside in the ICU with supine position. Diaphragmatic thickness was measured by placing the ultrasound on 8th-10th intercostal space between anterior and mid-axillary line with marker at 12 o'clock. B-mode ultrasound was used to measure the distance between thoracic and abdominal diaphragm which resulted in the diaphragmatic thickness at inspiration (DTi) and diaphragmatic thickness at expiration (DTe).~The ultrasound was then placed on the subcostal area between anterior and mid-axillary line with marker at 12 o'clock to observe the diaphragmatic motion on each side. Measurement of diaphragmatic excursion as well as recording and evaluation of diaphragmatic sliding and motion were performed during both inspiration and expiration using M-mode.
Study NCT06766045 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluoroscopy
Description: Fluoroscopy test was conducted in cathlab with supine position and anteroposterior (AP) projection for at least 5 breathing cycles. The fluoroscopy recording was then expertised and interpreted by the pediatric cardiologist in charge.
Study NCT06765460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical prescription of exercise
Description: MPE consists of dedicating a specific time to establish a specific and individualized exercise plan for the patient, with the premises of fully assessing their physical fitness, motivation, adaptability to change and the possibility of exercising within their social environment, as well as the achievement of specific objectives within an agreed follow-up period
Study NCT06765460 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Advice
Description: HA consists of providing the patient with information and motivation in line with general international recommendations to try to increase PA levels in their daily life. This advice can be given in a short period of time (up to three minutes) during any medical consultation
Study NCT06764862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK44459 dose 1
Description: HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
Study NCT06764862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK44459 dose 2
Description: HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
Study NCT06764862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
Study NCT06768294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib 4 MG Oral Tablet
Description: Baricitinib is a JAK1/JAK2 inhibitor approved for use in Rheumatoid Arthritis. It is under investigation for use in several inflammatory diseases, including Psoriasis and Psoriatic Arthritis, Atopic Dermatitis, Inflammatory Bowel Disease and Systemic Lupus Erythematosus, with encouraging results. As IL-6 plays a central role in CPPD inflammatory process, a broad spectrum of interleukins and other proinflammatory proteins (including interferons) could be involved. A drug that acts by blocking more than one proinflammatory cytokine could be a promising treatment for a multifaceted disease such as CPPD.
Study NCT06768294 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Methylprednisolone (Corticosteroid)
Description: The initial dosage of methylprednisolone may vary depending on the entity of inflammation and the patient's comorbidities. Usually in CPPD a short-term administration of methylprednisolone starts with 16 mg per day after breakfast decreasing the initial dosage in small decrements at appropriate time intervals until discontinuation, in about 2 weeks. Methylprednisolone will be given in combination with gastroprotective agents such as proton pump inhibitors.
Study NCT06768294 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Colchicine 1 MG Oral Tablet
Description: 1 or ½ tablet (depending on individual tolerance) daily after breakfast
Study NCT06768294 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Hydroxychloroquine 200 mg
Description: 1 tablet daily after lunch
Study NCT06768294 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Methotrexate + Folic Acid
Description: MTX 2.5 mg tablets, from 2 to 4 tablets (5-10mg), depending on disease severity, to be administered once weekly after dinner, always in the same day of the week. One tablet of folic acid (folina 5 mg) will be administered the day after MTX administration, after breakfast, to reduce and prevent the common side effects of MTX.
Study NCT06767930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand and Arm Bimanual Intensive Therapy Including Lower Extremities
Description: The HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) program is an intensive rehabilitation therapy designed to improve motor functions and promote functional independence. Participants in this arm will engage in 6.5 hours of structured activities per day for two weeks (10 days). The therapy focuses on bimanual coordination combined with constant stimulation of the trunk and/or lower extremities, using task-oriented exercises tailored to individual goals. Each participant will be supported by one or two therapists and supervised by a trained team to ensure the program is delivered effectively and safely. The therapy emphasizes engaging, play-based activities to maximize motivation and active participation.
Study NCT06767930 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional intervention
Description: Participants in the control group will continue their usual care, which includes conventional physical and occupational therapy, for a duration of two weeks. They will follow their regular therapy schedules without any changes to their routines or treatment habits. This approach ensures that the control group reflects standard rehabilitation practices, allowing for a direct comparison with the intervention group.
Study NCT06769243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Transcranial Magnetic Stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain. It is primarily used to treat OCD, particularly in patients who have not responded well to traditional treatments such as medications or psychotherapy. The most common target is the supplementary motor area (SMA), which has an indirect connection with the Cortico-Striato-Thalamo-Cortical (CSTC) pathway, known to be hyperactive in OCD.~Another option to target the CSTC pathway is deep TMS, although it is not available in most advanced centers. The magnetic pulses from TMS stimulate or inhibit brain activity in the targeted area, which is believed to help reset or correct neural activity patterns associated with OCD and other psychiatric disorders.~TMS represents an alternative treatment for those struggling with OCD, offering a non-invasive approach with relatively few side effects and significant potential benefits.
Study NCT06767527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: AK112 via intravenous (IV) infusion
Study NCT06767527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-Paclitaxel 100mg/m2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle
Study NCT06767527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-Paclitaxel 100mg/m2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle
Study NCT06767527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo via IV infusion
Study NCT06765330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHX disinfection
Description: Each CHX cavity will be treated with disinfectant with a disposable micro brush tip and left undisturbed for 20 seconds. They will then be air-dried for 10 seconds and restore the tooth.
Study NCT06765330 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Disinfection
Description: After the caries removal procedure, the cavity will be disinfected using an Er,Cr: YSGG laser (EPIC X™, BIOLASE, USA) with 940 nm and 0.1 W output power. The laser tip will be a 400 µm tip with an energy density of 138.12 J/cm in non-contact mode (2 mm distance), 5 s/mm2 sweeping motion.
Study NCT06765330 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tungsten carbide bur
Description: Carious tissue will be completely removed from the surrounding cavity walls with a tungsten carbide bur, leaving at least 2 mm of peripheral intact tooth structure for good adaptation and sealing of the restoration.
Study NCT06765330 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Polymer bur
Description: Access to the lesion will be achieved using a high-speed handpiece with a sterile high-speed bur. The polymer bur will be used with a low-speed handpiece at 5,000-10,000 RPM to remove carious dentin in sizes RA4, RA6, and RA8 according to the size of the caries lesion. The instrument will be used with a circular, light force starting from the center of the carious lesion towards the periphery as recommended by the manufacturer. Caries removal will be stopped when the instrument is macroscopically worn and blunt and can no longer remove tissue. An excavator will be used to verify if any caries remain at the base of the cavity. If necessary, a new polymer bur will be used to remove the remaining decay.
Study NCT06765824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: The protocol will be applied with the MagVenture R30 stimulation device and the cool-B70 coil for active treatment. The protocol will consist of two sessions per day, with a 50-minute break between sessions, every day of the week (Monday to Friday) for three and a half weeks (a total of 36 sessions). Each session will consist of the application of a 1Hz protocol (2000 pulses at 120% of the motor threshold) in the right dorsolateral prefrontal cortex (F4) followed by an intermittent theta-burst protocol (1800 pulses at 90% of the motor threshold) in the left dorsolateral prefrontal cortex (F3). The cortical target localization will be performed using the beam-F3/F4 technique that combines different electroencephalographic positioning parameters and measurements to accurately locate said cortical targets. The motor threshold of each patient will be calculated at the beginning of each week of treatment using an electromyography system.
Study NCT06765824 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation Sham
Description: The same protocol described in the intervention group will be carried out in the control group. The device used is the same, the difference is the coil that maintains the same appearance and generates the same sound as the active treatment coil, but unlike the latter, it does not produce an effective magnetization to depolarize the cerebral cortex on which we act.
Study NCT06766734 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tendon Dry Needling
Description: Tendon dry needling procedure is that repetitively passing the needle though the area of supraspinatus tendon. Tendon dry needling was performed under sterile conditions with real-time imaging guidance using an ultrasound probe. The supraspinatus tendon was scanned from anterior to posterior, and tendon dry needling was applied to the identified lesion (tendinozis or partial tear) area. This treatment method was applied twice, with a one-month interval between sessions.
Study NCT06766734 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Tendon Dry Needling
Description: In this treatment subcutaneous sham tendon dry needling was performed by randomly holding the ultrasound probe in the area corresponding to the same anatomical localization. Sham tendon dry needling performed to subcutaneus tissue not tendon.
Study NCT06765928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selinexor in combination with venetoclax
Description: After allo-HSCT, intermediate-high risk MDS/AML patients are maintenanced with selinexor given in combination with venetoclax for 2 years
Study NCT06769321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic Thermo-mechanical Massage Bed
Description: The MASTER V6 (Master series, CGM MB-1701, CERAGEM Co. Ltd., Cheonan, Korea) used in this study is a commercially available automated thermo-mechanical therapy device that combines mechanical spinal stimulation with far-infrared (FIR) heat treatment.
Study NCT06769321 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Automatic Thermo-mechanical Massage Bed
Description: The MASTER V6 (Master series, CGM MB-1701, CERAGEM Co. Ltd., Cheonan, Korea) used in this study is a commercially available automated thermo-mechanical therapy device that combines mechanical spinal stimulation with far-infrared (FIR) heat treatment.
Study NCT06766669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shaping method activities combined with mirror therapy
Description: This intervention involves the application of exercises consisting of shaping method activities accompanied by a mirror device. It is basically an intervention consisting of exercises that require manual dexterity.
Study NCT05303766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radio-frequency ablation
Description: Radiofrequency thermocoagulation of the genicular nerves